As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

As the first treatment cleared by the FDA for Demodex blepharitis, an eye disease estimated to affect 25 million people in ...

After Viatris’ CEO earlier this year promised to be “opportunistic” about future business development moves, the company is ...

AbbVie made history in 2015 with its Parkinson’s disease infusion pump therapy Duopa, kicking off a trend of delivery system ...

Eli Lilly has thrown its weight behind a cause beyond the traditional remit of pharma companies. | Eli Lilly has thrown its ...

With the clade 1 outbreak of mpox (formerly monkeypox) raging through the Congo and other countries in Central Africa, ...

While radiopharmaceuticals have attracted significant interest in recent years thanks to their cancer-fighting prowess, the ...

OmniaBio, a CDMO focused on cell and gene therapies, debuted a new manufacturing facility it claims to be the largest of its ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...

The more healthcare professionals (HCPs) know the pharma industry, the more they trust the pharma industry. That is the claim ...

As Sanofi moves forward with talks to potentially sell a 50% stake its consumer health unit Opella, fears of job cuts and ...

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...